BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Theivanthiran B, Evans KS, DeVito NC, Plebanek M, Sturdivant M, Wachsmuth LP, Salama AK, Kang Y, Hsu D, Balko JM, Johnson DB, Starr M, Nixon AB, Holtzhausen A, Hanks BA. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest 2020;130:2570-86. [PMID: 32017708 DOI: 10.1172/JCI133055] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 40.0] [Reference Citation Analysis]
Number Citing Articles
1 Tengesdal IW, Dinarello A, Powers NE, Burchill MA, Joosten LAB, Marchetti C, Dinarello CA. Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. Front Immunol 2021;12:661323. [PMID: 34531850 DOI: 10.3389/fimmu.2021.661323] [Reference Citation Analysis]
2 Wang H, Qi Y, Lan Z, Liu Q, Xu J, Zhu M, Yang T, Shi R, Gao S, Liang G. Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. Gene Ther 2022. [PMID: 35440807 DOI: 10.1038/s41434-022-00331-8] [Reference Citation Analysis]
3 Lv R, Raab M, Wang Y, Tian J, Lin J, Prasad PN. Nanochemistry advancing photon conversion in rare-earth nanostructures for theranostics. Coordination Chemistry Reviews 2022;460:214486. [DOI: 10.1016/j.ccr.2022.214486] [Reference Citation Analysis]
4 Homann L, Rentschler M, Brenner E, Böhm K, Röcken M, Wieder T. IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma. Cells 2022;11:1514. [DOI: 10.3390/cells11091514] [Reference Citation Analysis]
5 Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, Garcia-Granda MJ, Blanco E, Vera R, Kochan G, Escors D. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? Front Pharmacol 2020;11:441. [PMID: 32317979 DOI: 10.3389/fphar.2020.00441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
6 Xu J, Brosseau JP, Shi H. Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene 2020;39:7106-13. [PMID: 33024277 DOI: 10.1038/s41388-020-01491-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liang Q, Wu J, Zhao X, Shen S, Zhu C, Liu T, Cui X, Chen L, Wei C, Cheng P, Cheng W, Wu A. Establishment of tumor inflammasome clusters with distinct immunogenomic landscape aids immunotherapy. Theranostics 2021;11:9884-903. [PMID: 34815793 DOI: 10.7150/thno.63202] [Reference Citation Analysis]
8 Looi CK, Hii LW, Chung FF, Mai CW, Lim WM, Leong CO. Roles of Inflammasomes in Epstein-Barr Virus-Associated Nasopharyngeal Cancer. Cancers (Basel) 2021;13:1786. [PMID: 33918087 DOI: 10.3390/cancers13081786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Xiao Z, Singh S, Singh M. Improving cancer immunotherapy by targeting IL-1. Oncoimmunology 2021;10:2008111. [PMID: 34858734 DOI: 10.1080/2162402X.2021.2008111] [Reference Citation Analysis]
10 Tengesdal IW, Menon DR, Osborne DG, Neff CP, Powers NE, Gamboni F, Mauro AG, D'Alessandro A, Stefanoni D, Henen MA, Mills TS, De Graaf DM, Azam T, Vogeli B, Palmer BE, Pietras EM, DeGregori J, Tan AC, Joosten LAB, Fujita M, Dinarello CA, Marchetti C. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci U S A 2021;118:e2000915118. [PMID: 33649199 DOI: 10.1073/pnas.2000915118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
11 Khasraw M, Reardon DA, Weller M, Sampson JH. PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? Clin Cancer Res 2020;26:5287-96. [PMID: 32527943 DOI: 10.1158/1078-0432.CCR-20-1135] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
12 Liu X, Hogg GD, DeNardo DG. Rethinking immune checkpoint blockade: 'Beyond the T cell'. J Immunother Cancer 2021;9:e001460. [PMID: 33468555 DOI: 10.1136/jitc-2020-001460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
13 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Reference Citation Analysis]
14 Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer 2021;2:891-903. [PMID: 34796337 DOI: 10.1038/s43018-021-00234-4] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zhan L, Zhang J, Zhang J, Liu X, Zhu S, Shi Y, He Y, Wang W, Fan Y, Tang Z, Chen G, Wei B, Cao Y. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer. Cancer Lett 2021;529:37-52. [PMID: 34974132 DOI: 10.1016/j.canlet.2021.12.031] [Reference Citation Analysis]
16 Guo W, Ma J, Guo S, Wang H, Wang S, Shi Q, Liu L, Zhao T, Yang F, Chen S, Chen J, Zhao J, Yu C, Yi X, Yang Y, Ma J, Ni Q, Zhu G, Gao T, Li C. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma. J Immunother Cancer 2020;8:e001866. [PMID: 33298620 DOI: 10.1136/jitc-2020-001866] [Reference Citation Analysis]
17 Magkouta SF, Vaitsi PC, Pappas AG, Iliopoulou M, Kosti CN, Psarra K, Kalomenidis IT. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy. Cancers (Basel) 2021;13:2546. [PMID: 34067348 DOI: 10.3390/cancers13112546] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Espinoza JL, Kamio K, Lam VQ, Takami A. The Impact of NLRP3 Activation on Hematopoietic Stem Cell Transplantation. Int J Mol Sci 2021;22:11845. [PMID: 34769275 DOI: 10.3390/ijms222111845] [Reference Citation Analysis]
19 Huang Q, Lei Y, Li X, Guo F, Liu M. A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance. Front Cell Dev Biol 2020;8:580140. [PMID: 33344447 DOI: 10.3389/fcell.2020.580140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, Nanni P, Lollini PL, Palladini A. IFN-γ and CD38 in Hyperprogressive Cancer Development. Cancers (Basel) 2021;13:309. [PMID: 33467713 DOI: 10.3390/cancers13020309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zhang T, Ding S, Wang R. Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome. Int J Mol Sci 2021;22:10866. [PMID: 34639204 DOI: 10.3390/ijms221910866] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Tang F, Tie Y, Hong W, Wei Y, Tu C, Wei X. Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection. Ann Surg Oncol 2021;28:4030-48. [PMID: 33258011 DOI: 10.1245/s10434-020-09371-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Zhang H, Lin J, Shen Y, Pan J, Wang C, Cheng L. Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF-κB Pathway. JIR 2022;Volume 15:1653-66. [DOI: 10.2147/jir.s348464] [Reference Citation Analysis]
24 Zhai Z, Samson JM, Yamauchi T, Vaddi PK, Matsumoto Y, Dinarello CA, Ravindran Menon D, Fujita M. Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma. Cancers (Basel) 2020;12:E2518. [PMID: 32899791 DOI: 10.3390/cancers12092518] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Li Y, Lv J, Shi W, Feng J, Liu M, Gan S, Wu H, Fan W, Shi M. Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy. Front Immunol 2021;12:710110. [PMID: 34421915 DOI: 10.3389/fimmu.2021.710110] [Reference Citation Analysis]
26 Hudson K, Cross N, Jordan-Mahy N, Leyland R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020;11:568931. [PMID: 33193345 DOI: 10.3389/fimmu.2020.568931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Hamarsheh S, Groß O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun 2020;11:5439. [PMID: 33116132 DOI: 10.1038/s41467-020-19288-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
28 Theivanthiran B, Haykal T, Cao L, Holtzhausen A, Plebanek M, DeVito NC, Hanks BA. Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis. Cancers (Basel) 2021;13:4753. [PMID: 34638239 DOI: 10.3390/cancers13194753] [Reference Citation Analysis]
29 Li T, Liu T, Zhu W, Xie S, Zhao Z, Feng B, Guo H, Yang R. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. Clin Med Insights Oncol 2021;15:11795549211035540. [PMID: 34408525 DOI: 10.1177/11795549211035540] [Reference Citation Analysis]
30 Quagliariello V, De Laurentiis M, Cocco S, Rea G, Bonelli A, Caronna A, Lombari MC, Conforti G, Berretta M, Botti G, Maurea N. NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. Int J Mol Sci 2020;21:E7802. [PMID: 33096896 DOI: 10.3390/ijms21207802] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
31 Hong W, Xue M, Jiang J, Zhang Y, Gao X. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res 2020;39:149. [PMID: 32746878 DOI: 10.1186/s13046-020-01648-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
32 DeVito NC, Sturdivant M, Thievanthiran B, Xiao C, Plebanek MP, Salama AKS, Beasley GM, Holtzhausen A, Novotny-Diermayr V, Strickler JH, Hanks BA. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep 2021;35:109071. [PMID: 33951424 DOI: 10.1016/j.celrep.2021.109071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Lipinski S, Tiemann K. Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumor-Immune Interactions. Int J Mol Sci 2021;22:3374. [PMID: 33806053 DOI: 10.3390/ijms22073374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Targeting Innate Immunity in Cancer Therapy. Vaccines (Basel) 2021;9:138. [PMID: 33572196 DOI: 10.3390/vaccines9020138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
35 Sahin I, George A, Zhang S, Huntington KE, Ordulu Z, Zhou L, El-Deiry WS. Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget 2021;12:2131-46. [PMID: 34676046 DOI: 10.18632/oncotarget.28086] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Front Cell Dev Biol 2020;8:672. [PMID: 32793604 DOI: 10.3389/fcell.2020.00672] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
37 Sharma BR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol 2021;22:550-9. [PMID: 33707781 DOI: 10.1038/s41590-021-00886-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
38 Chung C, Seo W, Silwal P, Jo EK. Crosstalks between inflammasome and autophagy in cancer. J Hematol Oncol 2020;13:100. [PMID: 32703253 DOI: 10.1186/s13045-020-00936-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
39 Sonnessa M, Cioffi A, Brunetti O, Silvestris N, Zito FA, Saponaro C, Mangia A. NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. Front Oncol 2020;10:1587. [PMID: 33014808 DOI: 10.3389/fonc.2020.01587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
40 Zhou B, Gao Y, Zhang P, Chu Q. Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. Front Immunol 2021;12:693609. [PMID: 34194441 DOI: 10.3389/fimmu.2021.693609] [Reference Citation Analysis]
41 Ju M, Bi J, Wei Q, Jiang L, Guan Q, Zhang M, Song X, Chen T, Fan J, Li X, Wei M, Zhao L. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform 2021;22:bbaa345. [PMID: 33212483 DOI: 10.1093/bib/bbaa345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
42 Deets KA, Vance RE. Inflammasomes and adaptive immune responses. Nat Immunol 2021;22:412-22. [PMID: 33603227 DOI: 10.1038/s41590-021-00869-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
43 Li C, Qiu J, Xue Y. Low-dose Diosbulbin-B (DB) activates tumor-intrinsic PD-L1/NLRP3 signaling pathway mediated pyroptotic cell death to increase cisplatin-sensitivity in gastric cancer (GC). Cell Biosci 2021;11:38. [PMID: 33579380 DOI: 10.1186/s13578-021-00548-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
44 Finke D, Heckmann MB, Salatzki J, Riffel J, Herpel E, Heinzerling LM, Meder B, Völkers M, Müller OJ, Frey N, Katus HA, Leuschner F, Kaya Z, Lehmann LH. Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation. Cancers (Basel) 2021;13:2498. [PMID: 34065419 DOI: 10.3390/cancers13102498] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
45 Perrichet A, Ghiringhelli F, Rébé C. Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency. Cancers (Basel) 2020;12:E3550. [PMID: 33261061 DOI: 10.3390/cancers12123550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 2021;6:424. [PMID: 34924562 DOI: 10.1038/s41392-021-00827-6] [Reference Citation Analysis]